SRPT (Sarepta Therapeutics) Stock Analysis - Politician Trades

Sarepta Therapeutics (SRPT) is a publicly traded Healthcare sector company. As of May 21, 2026, SRPT trades at $17.25 with a market cap of $1.80B and a P/E ratio of 23.37. SRPT moved +2.88% today. Year to date, SRPT is -18.75%; over the trailing twelve months it is -57.19%. Its 52-week range spans $10.42 to $138.81. Analyst consensus is neutral with an average price target of $21.64. Rallies surfaces SRPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded SRPT stock?

Rallies tracks politician and congressional stock disclosures for SRPT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

SRPT Key Metrics

Key financial metrics for SRPT
MetricValue
Price$17.25
Market Cap$1.80B
P/E Ratio23.37
EPS$0.73
Dividend Yield0.00%
52-Week High$138.81
52-Week Low$10.42
Volume2.49K
Avg Volume0
Revenue (TTM)$2.18B
Net Income$65.06M
Gross Margin0.00%

Latest SRPT News

Recent SRPT Insider Trades

  • Mayo Stephen sold 7.24K (~$123.21K) on Mar 12, 2026.
  • Estepan Ian Michael sold 13.19K (~$294.20K) on Dec 16, 2025.
  • Nicaise Claude sold 2.49K (~$248.20K) on Mar 12, 2025.

SRPT Analyst Consensus

24 analysts cover SRPT: 0 strong buy, 6 buy, 13 hold, 5 sell, 0 strong sell. Consensus rating is neutral. Average price target: $21.64.

Common questions about SRPT

Which politicians traded SRPT stock?
Rallies tracks politician and congressional stock disclosures for SRPT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in SRPT?
Yes. Rallies tracks politician and congressional stock disclosures for SRPT, including reported purchases, sales, dates, owners, and trade amounts when available.
Is SRPT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SRPT. It does not provide personalized investment advice.
SRPT

Sarepta Therapeutics